March 18 (Reuters) - Bristol-Myers Squibb Co ( BMY ):

* BRISTOL MYERS SQUIBB COMPLETES ACQUISITION OF KARUNA

THERAPEUTICS, STRENGTHENING NEUROSCIENCE PORTFOLIO

* BRISTOL-MYERS SQUIBB CO ( BMY ): TRANSACTION TO RESULT IN ABOUT

$12

BILLION ONE-TIME, NON-DEDUCTIBLE ACQUIRED IN-PROCESS RESEARCH

AND DEVELOPMENT CHARGE

* BRISTOL-MYERS SQUIBB CO ( BMY ): ACQUIRED IPR&D CHARGE TO IMPACT

BOTH

2024 Q1 AND FULL-YEAR GAAP AND NON-GAAP EPS BY ABOUT $5.93

Source text for Eikon:

Further company coverage: